1-3 of 3
Weidong Jiang
Close
Sort by
Journal Articles

First China Approved Rituximab Biosimilar HLX01: Pharmacokinetics, Safety and Efficacy Comparison to Reference Rituximab in the Phase 3 Diffuse Large B-Cell Lymphoma Study

Yuankai Shi, MD PhD, Yongping Song, MD PhD, Yan Qin, MD PhD, Qingyuan Zhang, MD, Xiaohong Han, MD, Xiaonan Hong, MD, Dong Wang, MD, Xiaofeng Zeng, MD PhD, Pei Hu, MD PhD, Shuiyu Zhao, Kaka Y. Hong, MSSB, Chaoming Ma, Jiancheng Cheng, Peng Ting, PhD, Kevin Li, MD, Weidong Jiang, PhD, Scott Liu, PhD, Eugene Liu, MD PhD, Xin Zhang, MD, Katherine Chai, PhD MsLaw, Dan Yao, PhD, Alvin Y. Luk, PhDMBA
Journal: Blood
Blood (2019) 134 (Supplement_1): 2878.
https://doi.org/10.1182/blood-2019-130603
Published: 2019
Journal Articles

Overexpression of delta-like 4 induces arterialization and attenuates vessel formation in developing mouse embryos

Alexandre Trindade, S. Ram Kumar, Jeffrey S. Scehnet, Luis Lopes-da-Costa, Jorg Becker, Weidong Jiang, Ren Liu, Parkash S. Gill, Antonio Duarte
Journal: Blood
Blood (2008) 112 (5): 1720–1729.
https://doi.org/10.1182/blood-2007-09-112748
Published: 2008
Includes: Supplemental data
Journal Articles

Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion

Jeffrey S. Scehnet, Weidong Jiang, S. Ram Kumar, Valery Krasnoperov, Alexandre Trindade, Rui Benedito, Dusan Djokovic, Cristina Borges, Eric J. Ley, Antonio Duarte, Parkash S. Gill
Journal: Blood
Blood (2007) 109 (11): 4753–4760.
https://doi.org/10.1182/blood-2006-12-063933
Published: 2007
Includes: Supplemental data